C Diff Drug Development

Joseph Zackular, PhD suggests that mRNA vaccines and monoclonal antibodies could offer more effective treatments for recurrent C difficile infections

Pfizer Pflash: A Spotlight on Clostridioides difficile Vaccine Development Presentation intended for 1 ...

Vedanta Biosciences offered further insights on its completed phase 2 trial for its novel therapeutic, VE303.

Joseph Zackular, PhD, shares insights on his team’s mRNA vaccine research for C difficile, highlighting progress in animal models and future plans for human trials.

Clostridioides difficile is a major cause of nosocomial infections, often associated with individuals who have gut dysbiosis from previous antibiotic therapies. C. difficile infections (CDI) have a high recurrence rate and impose significant financial and mortality burdens on the healthcare system. …

Based on our findings, we elucidate a novel mechanism by which PAMK alleviates DSS-induced colitis and thus provides evidence to support the potential development of PAMK as a new clinical drug against UC.

To investigate whether the polysaccharide component of the Traditional Chinese Medicine (TCM) formula Lizhong decoction (LZD) has therapeutic effects and regulates gut microbiota in antibiotic-associated diarrhea (AAD) related to Clostridium difficile infection, a polysaccharide was extracted from L …

Acurx Pharmaceuticals (ACXP – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on December 10. Analyst Ed...

Acurx prepares for Phase 3 trials in C. difficile treatment

Clostridioides difficile is a gram-positive bacteria that causes disease in persons with dysbiosis of the gut microbiota and has been listed as an urgent threat due to the emergence of resistance.

Enteric pathogens are studied and antigens identified, which can be designed, synthesized, and cloned into expression genetic vectors and used to transform plants through physical, chemical, and biol...

Albany United States As per DelveInsight s assessment globally Clostridium Difficile Infections pipeline constitutes 20 key companies continuously working towards developing 22 Clostridium Difficile Infections treatment therapies analysis of Clinical Trials Therapies Mechanism of Action Route of Administration and Developments ...

Researchers in the USA investigated an mRNA-lipid nanoparticle (LNP) vaccine platform to prevent Clostridioides difficile infection and disease. The vaccine constructs contained TcdA, TcdB, and PPEP-1 sequences that were well conserved across genetically diverse strains of C difficile. In mice, a bivalent (TcdA–TcdB) or trivalent (TcdA–TcdB–PPEP-1) vaccine elicited IgG responses that were two to four times higher than those elicited by a trivalent recombinant protein vaccine with alum adjuvant. All mice immunised with monovalent TcdA or TcdB mRNA-LNP vaccines survived lethal challenge with C difficile toxins, whereas those vaccinated with recombinant TcdA or TcdB died within 1 day of challenge.

Clostridioides difficile infection (CDI) recurs in one of five patients. Monoclonal antibodies targeting the virulence factor TcdB reduce disease recurrence, suggesting that an inadequate anti-TcdB response to CDI leads to recurrence. In patients with CDI, we discovered that IL-33 measured at diagno …

Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, has announced it has secured £1 million in grant funding from PACE (Pathways to Antimicrobial Clinical Efficacy).

Peripheral modification is often the main approach to optimize natural products for improved biological activity or desired physicochemical properties. This procedure inevitably increases molecular weight, often accompanied by undesired increased lipophilicity. Removing structural elements from natu …

Delivering drugs to gut tumors can be tricky. Researchers at Washington University in St. | Delivering drugs to gut tumors can be tricky. Researchers at Washington University in St. Louis have engineered an oral probiotic yeast to do the work for them, with the fungal cells able to release immune checkpoint inhibitors that shrank intestinal tumors in mice with colorectal cancer.

Patients in British hospitals with serious, antibiotic-resistant gut infections have little in common with snakebite victims overseas. But when scientists made an unlikely connection in 2018, it led to trials for a potential new treatment for antibiotic-resistant infections. In this …

Vaginal microbiome specialist Freya Bioscience ApS has added $11.8 million to its series A, bringing the total for the round to $50 million. Of the additional $11.8 million, $10.4 million comes from the Gates Foundation and is designated for the development of vaginal microbiome-based immunotherapies for treating bacterial vaginosis, a cause of preterm birth and other pregnancy complications.

Acurx Pharmaceuticals secures FDA agreement for Phase 3 trials of ibezapolstat in C. difficile treatment, showcasing positive microbiome data and international expansion plans.

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug discovery that is both first-in-class and best-in-class.

Clostridioides difficile infection (CDI) recurs in one of five patients. Monoclonal antibodies targeting the virulence factor TcdB reduce disease recurrence, suggesting that an inadequate anti-TcdB response to CDI leads to recurrence. In patients with CDI, we discovered that IL-33 measured at diagnosis predicts future recurrence, leading us to test the role of IL-33 signaling in the induction of humoral immunity during CDI. Using a mouse recurrence model, IL-33 was demonstrated to be integral for anti-TcdB antibody production. IL-33 acted via ST2+ ILC2 cells, facilitating germinal center T follicular helper (GC-Tfh) cell generation of antibodies. IL-33 protection from reinfection was antibody-dependent, as μMT KO mice and mice treated with anti-CD20 mAb were not protected. These findings demonstrate the critical role of IL-33 in generating humoral immunity to prevent recurrent CDI. ### Competing Interest Statement W.P. is a consultant for TechLab, Inc., which manufactures diagnostic tests for CDI. The authors declare no other competing interests.

A stay in a hospital might resolve one health challenge. Still, it may introduce another: an intractable infection with Clostridioides difficile (C difficile), wrote an Editors Summary published in the journal Science in October 2024. This bacteria can thrive and produce toxins if antibiotics hinder the normal gut bacteria.

Clostridioides difficile infection (CDI) is a common cause of antibiotic-associated colitis. C. difficile proliferates and produces toxins that damage the colonic epithelium, leading to symptoms ranging from mild diarrhea to severe pseudomembranous colitis. The host's innate response t …

Working with animals, Penn researchers modified the mRNA vaccine to target C. difficile, an infection that kills 30,000 in the U.S. each year.

The group of large clostridial toxins (LCTs) includes toxins A (TcdA) and B (TcdB) from Clostridioides difficile, hemorrhagic and lethal toxins from Paeniclostridium sordellii, alpha toxin from Clostridium novyi (TcnA), and cytotoxin from Clostridium perfringens. These toxins are associated with sev …

Global difficile-associated diarrhea treatment market size is expected at $5.16 Bn by 2028 at a growth rate of 12.1%.

Using COVID-19 vaccine technology, researchers created an mRNA vaccine targeting C difficile, showing strong immune responses in animal studies.